Reduced activation of intracellular signaling pathways in rat prefrontal cortex after chronic phencyclidine administration

Pharmacological Research

Volumn 57, Issue 4, 2008, Pages 296-302

  Molteni, Raffaella ^a   Pasini, Matteo ^a,d   Moraschi, Stefania ^b   Gennarelli, Massimo ^b,c   Drago, Filippo ^d   Racagni, Giorgio ^a,b   Riva, Marco A ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

Author keywords

Phencyclidine; Prefrontal cortex; Schizophrenia; Signaling

Indexed keywords

BETA ACTIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE; PROTEIN KINASE (CALCIUM,CALMODULIN) II;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COMMUNICATION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HIPPOCAMPUS; INFORMATION PROCESSING; MALE; NERVE CELL PLASTICITY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CELL COMMUNICATION; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MALE; NEURONAL PLASTICITY; PHENCYCLIDINE; PHOSPHORYLATION; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 42749095155     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.02.007     Document Type: Article

References (48)

1. Lieberman J.A., Kane J.M., and Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 91 (1987) 415-433
2. Creese I., Burt D.R., and Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192 (1976) 481-483
3. Olney J.W., Newcomer J.W., and Farber N.B. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33 (1999) 523-533
4. Glantz L.A., and Lewis D.A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 57 (2000) 65-73
5. Weinberger D.R., and Berman K.F. Prefrontal function in schizophrenia: confounds and controversies. Philos Trans R Soc Lond B Biol Sci 351 (1996) 1495-1503
6. Kristiansen L.V., Beneyto M., Haroutunian V., and Meador-Woodruff J.H. Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Mol Psychiatry 11 (2006) 737-747 705
7. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51 (1994) 199-214
8. Sams-Dodd F. Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav Pharmacol 8 (1997) 196-215
9. Linn G.S., and Javitt D.C. Phencyclidine (PCP)-induced deficits of prepulse inhibition in monkeys. Neuroreport 12 (2001) 117-120
10. Braff D.L., and Geyer M.A. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 47 (1990) 181-188
11. McGhie A., and Chapman J. Disorders of attention and perception in early schizophrenia. Br J Med Psychol 34 (1961) 103-116
12. Linn G.S., Negi S.S., Gerum S.V., and Javitt D.C. Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys. Psychopharmacology (Berl) 169 (2003) 234-239
13. Sams-Dodd F. Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev Neurosci 10 (1999) 59-90
14. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20 (1999) 201-225
15. Hertzmann M., Reba R.C., and Kotlyarov E.V. Single photon emission computed tomography in phencyclidine and related drug abuse. Am J Psychiatry 147 (1990) 255-256
16. Wu J.C., Buchsbaum M.S., and Bunney W.E. Positron emission tomography study of phencyclidine users as a possible drug model of schizophrenia. Yakubutsu Seishin Kodo 11 (1991) 47-48
17. Balla A., Koneru R., Smiley J., Sershen H., and Javitt D.C. Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release. Neuropsychopharmacology 25 (2001) 157-164
18. Kyosseva S.V., Owens S.M., Elbein A.D., and Karson C.N. Differential and region-specific activation of mitogen-activated protein kinases following chronic administration of phencyclidine in rat brain. Neuropsychopharmacology 24 (2001) 267-277
19. Spielewoy C., and Markou A. Withdrawal from chronic phencyclidine treatment induces long-lasting depression in brain reward function. Neuropsychopharmacology 28 (2003) 1106-1116
20. Mandillo S., Rinaldi A., Oliverio A., and Mele A. Repeated administration of phencyclidine, amphetamine and MK-801 selectively impairs spatial learning in mice: a possible model of psychotomimetic drug-induced cognitive deficits. Behav Pharmacol 14 (2003) 533-544
21. Abe S., Suzuki T., Ito T., Yamaguchi M., Baba A., Hori T., et al. Effects of single and repeated phencyclidine administration on the expression of metabotropic glutamate receptor subtype mRNAs in rat brain. Neuropsychopharmacology 25 (2001) 173-184
22. Paxinos G.W.C. The rat brain in stereotaxic coordinates (1996), Academic Press, New York
23. Dunah A.W., and Standaert D.G. Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J Neurosci 21 (2001) 5546-5558
24. Fumagalli F., Molteni R., Calabrese F., Frasca A., Racagni G., and Riva M.A. Chronic fluoxetine administration inhibits extracellular signal-regulated kinase 1/2 phosphorylation in rat brain. J Neurochem 93 (2005) 1551-1560
25. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162 (1987) 156-159
26. Colbran R.J., and Brown A.M. Calcium/calmodulin-dependent protein kinase II and synaptic plasticity. Curr Opin Neurobiol 14 (2004) 318-327
27. Hashimoto T., and Lewis D.A. BDNF Val66Met polymorphism and GAD67 mRNA expression in the prefrontal cortex of subjects with schizophrenia. Am J Psychiatry 163 (2006) 534-537
28. Fumagalli F., Molteni R., Roceri M., Bedogni F., Santero R., Fossati C., et al. Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-d-aspartate receptor activity. J Neurosci Res 72 (2003) 622-628
29. Luo C., Xu H., and Li X.M. Post-stress changes in BDNF and Bcl-2 immunoreactivities in hippocampal neurons: effect of chronic administration of olanzapine. Brain Res 1025 (2004) 194-202
30. Lonze B.E., and Ginty D.D. Function and regulation of CREB family transcription factors in the nervous system. Neuron 35 (2002) 605-623
31. Fiore R.S., Murphy T.H., Sanghera J.S., Pelech S.L., and Baraban J.M. Activation of p42 mitogen-activated protein kinase by glutamate receptor stimulation in rat primary cortical cultures. J Neurochem 61 (1993) 1626-1633
32. Schwarzschild M.A., Cole R.L., Meyers M.A., and Hyman S.E. Contrasting calcium dependencies of SAPK and ERK activations by glutamate in cultured striatal neurons. J Neurochem 72 (1999) 2248-2255
33. Vanhoutte P., Barnier J.V., Guibert B., Pages C., Besson M.J., Hipskind R.A., et al. Glutamate induces phosphorylation of Elk-1 and CREB, along with c-fos activation, via an extracellular signal-regulated kinase-dependent pathway in brain slices. Mol Cell Biol 19 (1999) 136-146
34. Enomoto T., Noda Y., Mouri A., Shin E.J., Wang D., Murai R., et al. Long-lasting impairment of associative learning is correlated with a dysfunction of N-methyl-d-aspartate-extracellular signaling-regulated kinase signaling in mice after withdrawal from repeated administration of phencyclidine. Mol Pharmacol 68 (2005) 1765-1774
35. Sweatt J.D. Mitogen-activated protein kinases in synaptic plasticity and memory. Curr Opin Neurobiol 14 (2004) 311-317
36. Frodin M., and Gammeltoft S. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol 151 (1999) 65-77
37. Tardito D., Perez J., Tiraboschi E., Musazzi L., Racagni G., and Popoli M. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol Rev 58 (2006) 115-134
38. 2+/calmodulin-dependent protein kinase II pathway in the impairment of latent learning in a model of schizophrenia induced by phencyclidine. Mol Pharmacol 71 (2007) 1598-1609
39. 2+/calmodulin-dependent protein kinase II by protein phosphatases 1 and 2A. J Neurochem 68 (1997) 2119-2128
40. Genoux D., Haditsch U., Knobloch M., Michalon A., Storm D., and Mansuy I.M. Protein phosphatase 1 is a molecular constraint on learning and memory. Nature 418 (2002) 970-975
41. Takeuchi M., Ishida A., Kameshita I., Kitani T., Okuno S., and Fujisawa H. Identification and characterization of CaMKP-N, nuclear calmodulin-dependent protein kinase phosphatase. J Biochem 130 (2001) 833-840
42. Takeuchi M., Taniguchi T., and Fujisawa H. Identification and characterization of nuclear localization signals of CaMKP-N. J Biochem 136 (2004) 183-188
43. 2+/calmodulin-dependent protein kinase phosphatase causes developmental abnormalities in zebrafish. Arch Biochem Biophys 457 (2007) 205-216
44. Yasuda R., Sabatini B.L., and Svoboda K. Plasticity of calcium channels in dendritic spines. Nat Neurosci 6 (2003) 948-955
45. Andreasen N.C., O'Leary D.S., Flaum M., Nopoulos P., Watkins G.L., Boles Ponto L.L., et al. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet 349 (1997) 1730-1734
46. Beckmann H., and Senitz D. Developmental malformations in cerebral structures in "endogenous psychoses". J Neural Transm 109 (2002) 421-431
47. Weinberger D.R., Berman K.F., and Zec R.F. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch Gen Psychiatry 43 (1986) 114-124
48. Fumagalli F., Frasca A., Sparta M., Drago F., Racagni G., and Riva M.A. Long-term exposure to the atypical antipsychotic olanzapine differently up-regulates extracellular signal-regulated kinases 1 and 2 phosphorylation in subcellular compartments of rat prefrontal cortex. Mol Pharmacol 69 (2006) 1366-1372